Latest News, Press Releases & Events

Spyryx Biosciences Presents Development Update at Jefferies Cystic Fibrosis Summit

Spyryx Biosciences Presents Development Update at Jefferies Cystic Fibrosis Summit Progress Shared About Novel, First-In-Class Inhaled Peptide Treatment for Cystic Fibrosis DURHAM, N.C., Oct. 3, 2016 /PRNewswire/ — John Taylor, President and CEO of Spyryx Biosciences, a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, provided an update on the Company’s progress […]

Continue Reading

Spyryx Biosciences Appoints Alistair Wheeler, MD MFPM as Chief Medical Officer, SPX-101 Advancing in Phase 1 as Novel Therapy for Cystic Fibrosis

Spyryx Biosciences Expands Executive Team, Appoints Pulmonary Industry Leader, Alistair Wheeler, MD, MFPM as Chief Medical Officer Recognized Expert in Respiratory Product Development SPX-101 Advancing in Phase 1 as Novel Therapy for Cystic Fibrosis Durham, NC; August 18, 2016 – Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for respiratory diseases, including cystic […]

Continue Reading

Spyryx Biosciences Emerging Company Profile in BioCentury

EMERGING COMPANY PROFILE GOING SPLUNCING BY EMILY CUKIER-MEISNER, SENIOR WRITER Spyryx Biosciences Inc. is developing inhaled peptides for cystic fibrosis that inhibit the sodium channel responsible for regulating fluid volume in the lungs. The peptides could offer a pan-genotypic treatment that is more efficacious than therapies targeting CFTR. CF is caused by defects in the […]

Continue Reading